Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus-Based Immunosuppression in Kidney Transplant Recipients with Chronic Allograft Nephropathy
NCT00443508Phase 4Unknown
- Sponsor
- Rabin Medical Center
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in Chronic Allograft Kidney Disease (CKaD) (2 arms), sponsored by Rabin Medical Center. Primary endpoints: Creatinine levels at 12 months and Calculated creatinine clearance at 12 months. Status: unknown.
02
Drugs
everolimus
03
Conditions
Chronic Allograft Kidney Disease (CKaD)
Beyond the preview
Go deeper on NCT00443508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00443508.